Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA vaccine against COVID-19 shows promise in early trial

NCT ID NCT04673149

Completed ⭐️ VACCINE ⭐️ Sponsor: GeneOne Life Science, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new DNA vaccine called GLS-5310 for COVID-19 in 171 healthy adults aged 19 to 85. The vaccine is given as a shot under the skin and aims to teach the body to fight the virus. Researchers checked for side effects and measured immune responses like T cells and antibodies. The trial is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLS-5310 DNA vaccine
What this could lead to
If successful, this could lead to a new DNA-based vaccine option for COVID-19 that is easy to store and administer.
What could go wrong
This is an early-phase trial focused on safety and immune response, not yet proven to prevent infection. The vaccine may not generate strong enough immunity or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS COV-2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS COV-2

Contacts and locations

Locations

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.